Laninamivir
Based on 8 publication(s) in Google Scholar
Laninamivir (R 125489) is a potent influenza neuraminidase (NA) inhibitor with IC50s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.97%
- No. CAS: 203120-17-6
- Fòrmula: C13H22N4O7
- Peso molecular:346.34
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Laninamivir
More- Nat Commun. 2025 Jul 1;16(1):5831. [Abstract]
- NPJ Digit Med. 2025 Nov 21;8(1):712. [Abstract]
- PLoS Pathog. 2026 Jan 23;22(1):e1013863. [Abstract]
- Sci Rep. 2021 Aug 11;11(1):16293. [Abstract]
- Int J Infect Dis. 2024 Sep:146:107134. [Abstract]
- Microbiol Spectr. 2026 Feb 18:e0332825. [Abstract]
- Viruses. 2024 Sep 14;16(9):1467. [Abstract]
- PLoS One. 2018 Jul 12;13(7):e0200761. [Abstract]
Actividad biológica
IC50: 0.90 nM (N5), 1.83 nM (p09N1), 3.12 nM (p57N2)[1]
Laninamivir (R 125489) inhibits efficiently common oseltamivir-resistant viruses, including those with the ubiquitous His274Tyr substitution[1].
Laninamivir (R 125489) is potent against p57N2, p09N1 and N5 with a similar binding mode to Zanamivir[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 203120-17-6
-
Appearance Solid
-
Peso molecular 346.34
-
Fòrmula C13H22N4O7
-
Color White to off-white
-
SMILES
OC[C@@H](O)[C@H]([C@@]1([H])[C@@H]([C@H](C=C(C(O)=O)O1)NC(N)=N)NC(C)=O)OC
-
Synonyms
R 125489
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses. [Abstract]2025 Jul 1;16(1):5831. PMID: 40593518 -
NPJ Digit Med
Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]2025 Nov 21;8(1):712. PMID: 41272280 -
PLoS Pathog
Intra-patient neuraminidase mutations in avian H5N1 influenza virus reduce sialidase activity to complement weaker hemagglutinin binding and facilitate human infection. [Abstract]2026 Jan 23;22(1):e1013863. PMID: 41575943 -
Sci Rep
Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice. [Abstract]2021 Aug 11;11(1):16293. PMID: 34381119 -
Int J Infect Dis
Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. [Abstract]2024 Sep:146:107134. PMID: 38944411 -
Microbiol Spectr
Neuraminidase of influenza A viruses induces global desialylation of host cells via its intracellular function. [Abstract]2026 Feb 18:e0332825. PMID: 41705853 -
Viruses
The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro. [Abstract]2024 Sep 14;16(9):1467. PMID: 39339943 -
PLoS One
An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac. [Abstract]2018 Jul 12;13(7):e0200761. PMID: 30001430
Solvente y solubilidad
H2O : 5 mg/mL (14.44 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 3.12 mg/mL (9.01 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.8873 mL | 14.4367 mL | 28.8734 mL | 72.1834 mL |
| 5 mM | 0.5775 mL | 2.8873 mL | 5.7747 mL | 14.4367 mL | |
| 10 mM | 0.2887 mL | 1.4437 mL | 2.8873 mL | 7.2183 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Laninamivir Related Classifications
HY-14818 Related Classifications
Powered by Bioz